Search

Takeda Pharmaceutical Co Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

18.93 -0.63

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

18.91

Max

19

Pagrindiniai rodikliai

By Trading Economics

Pajamos

138B

113B

Pardavimai

105B

1.2T

P/E

Sektoriaus vid.

42.622

56.432

Pelnas, tenkantis vienai akcijai

0.48

Dividendų pajamingumas

3.38

Pelno marža

9.279

Darbuotojai

47,029

EBITDA

180B

337B

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+130.11% upside

Dividendai

By Acuity

Dividendų pajamingumas

Sektoriaus vid.

3.38%

2.27%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.7B

59B

Ankstesnė atidarymo kaina

19.56

Ankstesnė uždarymo kaina

18.93

Naujienos nuotaikos

By Acuity

100%

0%

320 / 339 reitingas Healthcare

Takeda Pharmaceutical Co Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-19 00:06; UTC

News

Hf Foods Group Inc. has terminated its $100 million equity offering program, with the stock declining in after-market trading following this decision.

2026-09-19 00:02; UTC

News

Block Inc is facilitating Ideal Nutrition's expansion to at least 20 U.S. locations, contributing to a modest increase in its stock during after-market hours.

2026-09-19 00:02; UTC

News
Social Media

MongoDB reported after-market earnings of $771.77 million and EPS of $1.90, exceeding estimates, with stock trading higher in line with market trends.

2026-09-19 00:02; UTC

News
Social Media

Accenture PLC and Anthropic announced a partnership to invest $1 billion each in AI safety, driving a significant increase in Accenture's stock price in after-hours trading.

2026-09-19 00:02; UTC

News

Shares lower in after-market as DOJ reviews antitrust lawsuit.

2026-09-19 00:02; UTC

News
Correlated Moves

Corning Inc's stock is modestly lower in after-market trading, potentially influenced by ASML Holding, despite four consecutive higher daily closes leading into this session.

2026-09-19 00:02; UTC

News

Kimberly-Clark Corp is higher in after-market trading following plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns.

2026-09-19 00:01; UTC

News

S&P Global Inc is experiencing modest gains in after-market trading, recovering from an early dip while remaining below its 20-day moving average.

2026-09-19 00:01; UTC

News

RTX Corp is seeing a modest decline in after-market trading, continuing a downward trend since Friday's close and remaining below its 20-day moving average.

2026-09-19 00:01; UTC

News

Union Pacific Corp shares are trading lower in after-market hours, despite UBS upgrading its rating to Buy and raising the price target to $339.

2026-09-18 23:41; UTC

News

Iovance Biotherapeutics granted inducement stock options for 179.75k shares to new employees, contributing to a modest decline in after-market hours.

2026-09-18 23:31; UTC

News

BlackRock Inc. shares are modestly lower in after-market trading amid heightened legal concerns as the DOJ considers intervention in an antitrust lawsuit against the company.

2026-09-18 23:26; UTC

News

State Street Corp declines in after-market trading as the U.S. Department of Justice considers intervention in a state antitrust lawsuit regarding energy price inflation.

2026-09-18 23:16; UTC

News

Union Pacific Corp's stock is trading higher in after-market hours following UBS's upgrade to Buy and a price target increase to $339, citing expected cargo growth.

2026-09-18 23:11; UTC

News

AutoNation Inc has been downgraded from Buy to Hold amid industry challenges, yet the stock is rising in after-market trading as the broader market advances.

2026-09-18 23:11; UTC

News

Leidos Holdings Inc. has secured an $85 million contract from the U.S. Department of War for aerospace systems design, with shares rising in after-market trading.

2026-09-18 23:06; UTC

News

AbbVie Inc. is experiencing a slight decline in after-market trading, positioned near the lower end of its recent trading range despite promising myeloma study results.

2026-09-18 23:06; UTC

News

Boeing is in talks with NASA to expand its Starliner program, potentially adding ten or more flights, as the stock moves higher in after-hours trading.

2026-09-18 23:06; UTC

News

Chevron Corp has declined in after-market trading, despite Goldman Sachs raising its price target to $240 and Piper Sandler setting an even higher target of $243.

2026-09-18 23:06; UTC

News

Okta Inc appointed Helen Riley to its board, enhancing leadership as shares rise in after-market trading, aligning with a broader market advance.

2026-09-18 23:06; UTC

News
Social Media

Nike shares are advancing in after-market hours despite recent challenges, including a significant decline and hitting a 12-year low.

2026-09-18 23:06; UTC

News

General Motors Co is advancing in after-market trading following its decision to reinstate Apple’s CarPlay and Android Auto in its vehicles.

2026-09-18 23:06; UTC

News

Medtronic PLC raised its fiscal 2027 profit forecast and reported first-quarter revenue of $9.756 billion, exceeding expectations, in after-market trading.

2026-09-18 23:06; UTC

News

RTX Corp's backlog hit a record $289 billion, with the stock advancing in after-market trading, despite remaining below its 20-day moving average.

2026-09-18 23:06; UTC

News

Celsius Holdings Inc shares are higher in after-market trading, continuing a positive trend despite ongoing legal scrutiny over its Alani Nu product line.

2026-09-18 23:01; UTC

News
Social Media

Northrop Grumman targets $10 billion in annual international sales by 2031, while shares trade lower in after-market hours.

2026-09-18 23:01; UTC

News

Kimberly-Clark Corp plans to divest assets related to its $40 billion Kenvue acquisition to address EU antitrust concerns, with shares modestly higher in after-market trading.

2026-09-18 23:01; UTC

Social Media
News

Accenture PLC announced a $1 billion partnership with Anthropic to enhance AI evaluation capabilities, leading to a sharp advance in shares during after-market hours.

2026-09-18 23:01; UTC

News

Bitcoin is sharply higher, trading well above its previous close amid a rally in the cryptocurrency market, driven by strong investor sentiment and recent Fed announcements.

2026-09-18 23:01; UTC

News

Ethereum is advancing sharply, continuing its upward trajectory alongside a broader cryptocurrency rally, despite earlier pulling back from a session high.

Akcijų palyginimas

Kainos pokytis

Takeda Pharmaceutical Co Ltd ADR Prognozė

Kainos tikslas

By TipRanks

130.11% į viršų

12 mėnesių prognozė

Vidutinis 43.513 USD  130.11%

Aukščiausias 43.513 USD

Žemiausias 43.513 USD

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Takeda Pharmaceutical Co Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.